GCM
VERV

Graham Capital Management’s Verve Therapeutics VERV Stock Holding History

Graham Capital Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-63,331
Closed -$289K – 1645
2025
Q1 		$289K Buy
63,331
+22,911
+57% +$153K 0.01% 1006
2024
Q4 		$228K Sell
40,420
-31,805
-44% -$179K ﹤0.01% 1035
2024
Q3 		$350K Sell
72,225
-70,289
-49% -$408K 0.01% 739
2024
Q2 		$695K Buy
142,514
+113,872
+398% +$716K 0.02% 488
2024
Q1 		$380K Buy
28,642
+16,057
+128% +$213K 0.01% 699
2023
Q4 		$175K Buy
+12,585
New +$156K ﹤0.01% 859

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Graham Capital Management's VERV Position: Q2 2025 in Review

Graham Capital Management sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 63,331 shares — an estimated $289K sold.

Graham Capital Management first reported a position in VERV in Q4 2023 and held it in 6 quarters. The position peaked at $695K in Q2 2024. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Graham Capital Management reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Graham Capital Management sold 63,331 Verve Therapeutics shares in Q2 2025, an estimated $289K.
  • Graham Capital Management first reported a position in Verve Therapeutics in Q4 2023 and held it in 6 quarters.
  • Graham Capital Management's Verve Therapeutics position peaked at $695K in Q2 2024.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Graham Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.